What DrugLoose gives you
Four data sets. One searchable place.
Market access teams at Indian and Asian pharma companies spend weeks stitching together country-level data from PDFs, government portals, and analyst reports. DrugLoose indexes that data into structured, searchable profiles.
Molecule search — any drug, any market
Type a molecule name, INN, or brand name. See structured clinical trial status, HTA decisions, reimbursement listings, and generic entry timelines across 54 countries — instantly.
- INN, brand name, or ATC code search
- Filters by country, therapy area, or status
- Exportable to Excel/CSV
Reference pricing across 54 countries
Compare ex-factory and retail prices in local currency and INR equivalents. Understand international reference pricing (IRP) exposure before launch — without paying for an enterprise contract.
- Ex-factory, wholesale, and retail price tiers
- INR equivalent for easy benchmarking
- Updated quarterly from public sources
HTA decisions and reimbursement status
Every major HTA body — NICE, G-BA, HAS, PBAC, CDSCO — tracked per molecule. See the decision date, assessment outcome, reimbursement conditions, and any managed-entry agreements in a single structured view.
- Decision dates and assessment outcomes
- Reimbursement conditions and restrictions
- Managed-entry agreement summaries
NICE (UK)
Mar 2013
G-BA (Germany)
Jan 2014
HAS (France)
Jun 2013
PBAC (Australia)
Nov 2015
Why DrugLoose
Enterprise intelligence. Without the enterprise price.
IQVIA, Citeline, and GlobalData are built for global enterprise procurement teams with seven-figure budgets. DrugLoose is built for everyone else: BD managers, regulatory affairs officers, CRO analysts, and researchers who need the same data without a sales call.
| Feature | DrugLoose | IQVIA | Citeline | GlobalData |
|---|---|---|---|---|
| Molecule-level search | ||||
| Country coverage (Asia-Pacific focus) | 54 countries | 60+ | 50+ | 50+ |
| HTA decisions database | ||||
| Generic entry tracking | ||||
| Pricing intelligence (INR reference) | ||||
| Subscription access (no contract) | ||||
| Individual / student plan | ||||
| Starting price (annual) | ₹18,000/yr | ₹85 lakh+ | ₹60 lakh+ | ₹50 lakh+ |
* Enterprise pricing estimated from publicly available contract disclosures and analyst reports. DrugLoose pricing listed at standard annual rate.
Before DrugLoose, we were spending three to four weeks per molecule pulling reimbursement data from country portals, HTA websites, and internal analyst notes. Now our market access team gets a structured brief in an afternoon. The pricing intelligence alone has informed two out of our last three BD decisions.
Priya Raghunathan
Head of Market Access, Biocon Biologics (sample testimonial)
Pricing
Straightforward annual plans
No enterprise contracts. No sales calls. Start a free 14-day trial of either plan; cancel anytime.
Researcher
₹18,000 billed annually
For students, independent consultants, and researchers who need structured molecule data without enterprise overhead.
- Search up to 500 molecules/month
- 20 countries covered
- Clinical trials + market access data
- CSV export (50 rows/month)
- Email support
Professional
₹78,000 billed annually
For market access managers, BD directors, and CRO teams that need the full data set across all covered markets.
- Unlimited molecule searches
- All 54 countries
- Pricing intelligence + HTA decisions
- Generic entry timelines
- Unlimited CSV / Excel export
- API access (beta)
- Priority support
Team plans (5+ users) and academic institution licences available on request.
Start searching in under two minutes
No sales call. No enterprise contract. Sign up, search your first molecule, and see what your team has been missing.
14 days free. No credit card required.